Willard H. Dere, MD, FACP

Languages

  • English

Academic Information

  • Departments: Internal Medicine - Professor
  • Divisions: Endocrinology and Metabolism

Board Certification

  • American Board of Internal Medicine

Academic Office Information

  • George and Dolores Eccles Institute of Human Genetics
    15 N 2030 E, Room: 2160
    Salt Lake City, UT 84112

Research Statement

Dr. Dere has extensive experience in clinical research during his 25 year stint in the biopharmaceutical industry. The experience was complemented by substantive regulatory and drug safety experience during that time. At the University of Utah, Dr. Dere serves as the Executive Director of the Program in Personalized Health and Co-Director of the Utah Center for Clinical and Translational Science.

While at Eli Lilly from 1989 to 2003, he conducted several clinical pharmacology Phase 1 studies with nasal insulin, several oral antibiotics, and PTH 1-34. He later served as executive director of the clinical pharmacology and the therapeutic areas charged with developing appropriate biomarkers, and proof-of-concept trials in several therapeutic areas. During this time, he supervised the clinical teams responsible for the development of the medicines duloxetine and atomoxetine. His phase 2 and 3 experiences were focused in endocrinology. He led the phase 2 and 3 programs for raloxifene, both in postmenopausal osteoporosis and breast cancer prevention, and PTH 1-34 in postmenopausal osteoporosis and glucocorticoid-induced osteoporosis. Hallmarks of these programs were the large fracture outcomes trials‹raloxifene (MORE) published in JAMA and PTH 1-34, published in the NEJM. From 2003 to 2014 at Amgen, Dr. Dere led the development programs of multiple medicines including denosumab marketed for both postmenopausal osteoporosis and prevention of deleterious skeletal outcomes from metastatic cancers; romiplostim for immune thrombocytopenic purpura; panitumumab for colorectal cancer; and cinacalcet for secondary hyperparathyroidism in end-stage renal disease. These programs involved extensive evaluation in both phase 2 and phase 3 clinical trials which occurred both in United States and non-American clinical trial sites, and the individual trials were published in prestigous biomedical journals.

Additionally, Dr. Dere was director of the Lilly European Regulatory and Safety department based in UK from 1991-1994, and a member of the CIOMS 3 Pharmacovigilance Working Group, sponsored by the World Health Organization. He has participated in a number of regulatory hearings at both the FDA and European Medicine Agency for approvals of oral antibiotics; raloxifene and PTH 1-34 in osteoporosis; and panitumumab for colorectal cancer. He has actively participated in a number of publications authored by academic, industry, and regulatory personnel which have served as the basis for subsequent guidelines for the European Medicines Agency.

Academic Bio

Dr. Dere has extensive experience in clinical research during his 25 year stint in the biopharmaceutical industry. The experience was complemented by substantive regulatory and drug safety experience during that time. At the University of Utah, Dr. Dere serves as the Executive Director of the Program in Personalized Health and Co-Director of the Utah Center for Clinical and Translational Science..

While at Eli Lilly from 1989 to 2003, he conducted several clinical pharmacology Phase 1 studies with nasal insulin, several oral antibiotics, and PTH 1-34. He later served as executive director of the clinical pharmacology and the therapeutic areas charged with developing appropriate biomarkers, and proof-of-concept trials in several therapeutic areas. During this time, he supervised the clinical teams responsible for the development of the medicines duloxetine and atomoxetine. His phase 2 and 3 experiences were focused in endocrinology. He led the phase 2 and 3 programs for raloxifene, both in postmenopausal osteoporosis and breast cancer prevention, and PTH 1-34 in postmenopausal osteoporosis and glucocorticoid-induced osteoporosis. Hallmarks of these programs were the large fracture outcomes trials‹raloxifene (MORE) published in JAMA and PTH 1-34, published in the NEJM. From 2003 to 2014 at Amgen, Dr. Dere led the development programs of multiple medicines including denosumab marketed for both postmenopausal osteoporosis and prevention of deleterious skeletal outcomes from metastatic cancers; romiplostim for immune thrombocytopenic purpura; panitumumab for colorectal cancer; and cinacalcet for secondary hyperparathyroidism in end-stage renal disease. These programs involved extensive evaluation in both phase 2 and phase 3 clinical trials which occurred both in United States and non-American clinical trial sites, and the individual trials were published in prestigous biomedical journals.

Additionally, Dr. Dere was director of the Lilly European Regulatory and Safety department based in UK from 1991-1994, and a member of the CIOMS 3 Pharmacovigilance Working Group, sponsored by the World Health Organization. He has participated in a number of regulatory hearings at both the FDA and European Medicine Agency for approvals of oral antibiotics; raloxifene and PTH 1-34 in osteoporosis; and panitumumab for colorectal cancer. He has actively participated in a number of publications authored by academic, industry, and regulatory personnel which have served as the basis for subsequent guidelines for the European Medicines Agency.

Education History

Type School Degree
Postdoctoral Training University of California, San Francisco
Endocrinology and Metabolism
Postdoctoral Training
Residency University of Utah
Internal Medicine
Resident
Internship University of Utah
Internal Medicine
Intern
Professional Medical University of California, Davis
Medicine
M.D.
Undergraduate University of California, Davis
History, Zoology
B.A.

Global Impact

Career

Institution Description Country
Eli Lilly and Company Director, European Pharmaceutical Registration and Scientific Advisor, Health Economics United Kingdom
Lilly Research Center Limited, Eli Lilly and Company Director, European Pharmaceutical Registration and Health Economics United Kingdom

News

Video